Danske Bank A S Reduces Stock Holdings in Corteva, Inc. $CTVA

Key Points

• Danske Bank A/S trimmed its Corteva stake by 11.5% in Q4, selling 86,658 shares and leaving it with 669,986 shares (about 0.10%) valued at $44.91M, while institutional investors own roughly 81.54% of the company.
• Insider Brian Titus sold 8,311 shares on Feb. 20 at about $76.55, reducing his position by 50.67%.
• Several analysts have raised price targets recently and the stock carries a consensus rating of Moderate Buy with a consensus target price of $86.38.

Danske Bank A S lowered its stake in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 11.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 669,986 shares of the company's stock after selling 86,658 shares during the quarter. Danske Bank A S owned 0.10% of Corteva worth $44,909,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of CTVA. Chilton Capital Management LLC raised its position in Corteva by 18.1% during the third quarter. Chilton Capital Management LLC now owns 445,350 shares of the company's stock worth $30,119,000 after acquiring an additional 68,380 shares during the period. Drummond Knight Asset Management Pty Ltd acquired a new stake in shares of Corteva in the fourth quarter valued at about $25,713,000. TriaGen Wealth Management LLC purchased a new stake in shares of Corteva during the third quarter worth about $4,284,000. Truist Financial Corp raised its position in shares of Corteva by 4.5% during the 3rd quarter. Truist Financial Corp now owns 321,913 shares of the company's stock worth $21,771,000 after purchasing an additional 13,910 shares during the last quarter. Finally, New York State Teachers Retirement System raised its position in shares of Corteva by 4.5% during the 3rd quarter. New York State Teachers Retirement System now owns 551,389 shares of the company's stock worth $37,290,000 after purchasing an additional 23,548 shares during the last quarter. Hedge funds and other institutional investors own 81.54% of the company's stock.

Insider Activity

In other Corteva news, insider Brian Titus sold 8,311 shares of the firm's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the sale, the insider directly owned 8,090 shares of the company's stock, valued at $619,289.50. This trade represents a 50.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.15% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on CTVA. BNP Paribas Exane lifted their price objective on Corteva from $72.00 to $74.00 in a report on Monday, March 9th. JPMorgan Chase & Co. cut Corteva from an "overweight" rating to a "neutral" rating and increased their target price for the company from $75.00 to $77.00 in a report on Thursday, February 5th. UBS Group raised their target price on Corteva from $80.00 to $88.00 and gave the company a "neutral" rating in a research report on Thursday, April 9th. Mizuho lifted their price target on Corteva from $82.00 to $94.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 15th. Finally, Oppenheimer increased their price objective on Corteva from $86.00 to $89.00 and gave the company an "outperform" rating in a research note on Wednesday, April 22nd. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $86.38.

Corteva Trading Down 0.1%

CTVA opened at $80.97 on Friday. The firm has a market capitalization of $54.36 billion, a price-to-earnings ratio of 51.24, a price-to-earnings-growth ratio of 2.78 and a beta of 0.59. The company's 50 day simple moving average is $80.39 and its two-hundred day simple moving average is $72.05. Corteva, Inc. has a 1-year low of $60.53 and a 1-year high of $85.63. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.96.

Corteva (NYSE:CTVA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The business had revenue of $3.91 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same period in the prior year, the business earned $0.32 earnings per share. The business's revenue was down 1.7% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Analysts expect that Corteva, Inc. will post 3.62 EPS for the current fiscal year.

Corteva Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Monday, June 1st will be issued a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.9%. The ex-dividend date is Monday, June 1st. Corteva's dividend payout ratio is presently 45.57%.

Corteva Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

Want to see what other hedge funds are holding CTVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corteva, Inc. (NYSE:CTVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.